menu
    • menu
    [{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Lerodalcibep","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"LIB Therapeutics","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.33000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"LIB Therapeutics \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"10","companyTruncated":"LIB Therapeutics \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lerodalcibep","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"LIB Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LIB Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lerodalcibep","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"LIB Therapeutics \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"10","companyTruncated":"LIB Therapeutics \/ Hasten Biopharmaceutic"}]

    Find Clinical Drug Pipeline Developments & Deals by LIB Therapeutics

    Menu

    LIB Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LIB Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            LIB Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lerodalcibep

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Hasten Biopharmaceutic

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LIB Therapeutics and Hasten Announce Acceptance of Lerodalcibep Clinical Trial Application

                            Details : LIB003 (lerodalcibep) is a potential best in class, novel, small binding protein, third-generation PCSK9 inhibitor, which is being evaluated for the treatment and prevention of cardiovascular disease.

                            Brand Name : LIB003

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 19, 2024

                            Lead Product(s) : Lerodalcibep

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Hasten Biopharmaceutic

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LIB Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            LIB Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lerodalcibep

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LIB Therapeutics Announces Completion of the Global Phase 3 LIBerate Program of Lerodalcibep, a Novel Third-Ge...

                            Details : LIB003 (lerodalcibep) is a novel, third-generation, PCSK9 inhibitor in development to overcome the limitations of current low density lipoprotein-cholesterol (LDL-C) lowering treatments, including statins and ezetimibe, to achieve the lower LDL-C.

                            Brand Name : LIB003

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 14, 2023

                            Lead Product(s) : Lerodalcibep

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            LIB Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            LIB Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lerodalcibep

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Hasten Biopharmaceutic

                            Deal Size : $325.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop...

                            Details : Under the terms of the agreement, LIB has granted Hasten the exclusive rights to develop and commercialize LIB003 (lerodalcibep), a next-generation, PCSK9 inhibitor, for patients at very high and high-risk of cardiovascular disease, in Greater China.

                            Brand Name : LIB003

                            Molecule Type : Large molecule

                            Upfront Cash : $20.0 million

                            September 12, 2023

                            Lead Product(s) : Lerodalcibep

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Hasten Biopharmaceutic

                            Deal Size : $325.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth